Solid Tumor

Why trials studying Solid Tumor stopped, in this sample of ClinicalTrials.gov.

37 stopped trials with a clear reason; 86% ended for non-scientific reasons.

Trials

• Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
  NCT07071909 · WITHDRAWN · funding business
  “Funding unavailable”
• A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
  NCT06364696 · TERMINATED · funding business
  “Company's strategic decision”
• Study of 23ME-01473 in Patients With Advanced Solid Malignancies
  NCT06290388 · TERMINATED · funding business
  “Sponsor cancelled study”
• BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
  NCT05935098 · TERMINATED · safety
  “This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the CCR8 program.”
• A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
  NCT05581719 · TERMINATED · funding business
  “Sponsor decision”
• Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors
  NCT05729399 · TERMINATED · funding business
  “The study was terminated from a business perspective.”
• A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
  NCT05346484 · TERMINATED · funding business
  “Portfolio prioritization”
• A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
  NCT05165849 · WITHDRAWN · funding business
  “sponsor decided to withdraw the study”
• Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
  NCT05262530 · TERMINATED · funding business
  “Sponsor decision”
• Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China
  NCT05120375 · TERMINATED · funding business
  “Based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline.”
• Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
  NCT04683939 · TERMINATED · funding business
  “Sponsor decision”
• Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
  NCT05221385 · TERMINATED · funding business
  “Due to changes in the sponsor's research strategy”
• The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
  NCT04696848 · TERMINATED · slow accrual
  “Recruitment difficulty”
• BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
  NCT04455620 · TERMINATED · funding business
  “Sponsor decision”
• A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
  NCT04671901 · TERMINATED · slow accrual
  “Lack of accrual”
• Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
  NCT04586335 · TERMINATED · funding business
  “Business decision”
• Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
  NCT04553692 · TERMINATED · funding business
  “Study terminated due strategic corporate pivot to focus on auto-immune indications”
• Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
  NCT04305249 · TERMINATED · funding business
  “The study was terminated based on the internal need to re-prioritization the whole pipeline and phase 1 portfolio.”
• Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
  NCT04347226 · TERMINATED · futility
  “Interim analysis indicated that futility boundary was reached.”
• A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
  NCT04172597 · TERMINATED · funding business
  “Strategic business decision (unrelated to safety)”
• A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
  NCT04209465 · TERMINATED · funding business
  “The development of BDTX-189 was discontinued by the sponsor.”
• Evaluate Eribulin ORA in Subjects With Solid Tumors
  NCT04013217 · TERMINATED · funding business
  “Sponsor Decision”
• A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib
  NCT03804515 · TERMINATED · logistics pi
  “COVID”
• Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
  NCT03875313 · TERMINATED · slow accrual
  “Slow Enrollment”
• A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
  NCT03960060 · TERMINATED · funding business
  “Adjustment of study strategy”
• Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
  NCT03834220 · TERMINATED · slow accrual
  “Due to lower antitumor activity than expected”
• Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
  NCT03680560 · TERMINATED · funding business
  “Business Reasons”
• Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy
  NCT03166176 · WITHDRAWN · futility
  “lack of efficacy”
• The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
  NCT03182673 · TERMINATED · funding business
  “Sponsor R \& D Strategy Adjustment”
• Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
  NCT01553071 · TERMINATED · logistics pi
  “drug supply issues during COVID-19”
• Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
  NCT02840110 · TERMINATED · funding business
  “Business Decision”
• Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
  NCT02624388 · TERMINATED · slow accrual
  “Poor enrollment”
• Medical Treatment Decision Making Using Adaptive Conjoint Analysis
  NCT02608307 · TERMINATED · slow accrual
  “Slow accrual and COVID-19 restrictions”
• LGX818 for Patients With BRAFV600 Mutated Tumors
  NCT01981187 · TERMINATED · slow accrual
  “Due to slow enrollment and lack of response observed during the enrollment period, the Sponsor decided to close study enrollment early on 28 January 2015”
• An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
  NCT01929941 · TERMINATED · funding business
  “Business decision.”
• A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
  NCT01641575 · TERMINATED · futility
  “Registrational study did not meet endpoint so entire program (including CO-101-011) was terminated.”
• Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
  NCT00512798 · TERMINATED · futility
  “This study was terminated due to lack of efficacy”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.